Association of , , , , and Genes in Colorectal Cancer: A Systematic Review and Meta-Analysis

Overview

Journal Genet Res (Camb)

Specialty Genetics

Date 2022 Sep 8

PMID 36072013

Authors

Hongfeng Yan

Fuquan Jiang

Jianwu Yang

Affiliations

Soon will be listed here.

Abstract

Objectives: Accumulating evidence indicates that the expression and/or variants of several genes play an essential role in the progress of colorectal cancer (CRC). The current study is a meta-analysis undertaken to estimate the prognosis and survival associated with , , , , , and genes among CRC patients.

Methods: The authors searched PubMed, EMBASE, and Science Direct for relevant reports published between 2000 and 2020 and analyzed them to determine any relationship between the (immunohistochemically/sequencing-detected) gene expression and variants of the selected genes and the survival of CRC patients.

Results: The analysis included 34,074 patients from 64 studies. To evaluate association, hazard ratios (HRs) were estimated for overall survival (OS) or disease-free survival (DFS), with a 95% confidence interval (CIs). Pooled results showed that overexpression, mutation, or 4 loss of expression, mutations, and expression were associated with shorter OS. overexpression (HR: 0.137 (95% CI: 0.131-0.406)), loss of expression of or 4 (HR: 0.449 (95% CI: 0.146-0.753)), the mutations of (HR: 0.179 (95% CI: 0.126-0.485)), and expression (HR: 0.485 (95% CI: 0.772-0.198)) also presented risk for shorter DFS.

Conclusions: The present meta-analysis indicates that overexpression or underexpression and variants of , , 4, , and genes potentially acted as unfavorable biomarkers for the prognosis of CRC. The gene was not associated with prognosis.

Citing Articles

Immunohistochemical Analysis of the p53 Protein in Colorectal Cancer: A Clinicopathological Study.

Khursheed S, Ali T, Mushtaq M, Humayun S, Khan A, Akbar A Cureus. 2025; 16(12):e76172.

PMID: 39840194 PMC: 11750202. DOI: 10.7759/cureus.76172.

From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.

Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).

PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.

Aberrant β-Catenin Expression and Its Association With Epithelial-Mesenchymal Transition and Clinical Outcomes of Colorectal Cancer.

Hussein Z, Al Hassawi B, Ibraheem Q Cureus. 2024; 16(1):e53104.

PMID: 38414697 PMC: 10897760. DOI: 10.7759/cureus.53104.

Prognostic Biomarkers of Cell Proliferation in Colorectal Cancer (CRC): From Immunohistochemistry to Molecular Biology Techniques.

Kasprzak A Cancers (Basel). 2023; 15(18).

PMID: 37760539 PMC: 10526446. DOI: 10.3390/cancers15184570.

Epigenomic analysis of formalin-fixed paraffin-embedded samples by CUT&Tag.

Henikoff S, Henikoff J, Ahmad K, Paranal R, Janssens D, Russell Z Nat Commun. 2023; 14(1):5930.

PMID: 37739938 PMC: 10516967. DOI: 10.1038/s41467-023-41666-z.

References

Zhang M, Cui F, Lu S, Lu H, Jiang T, Chen J . Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014; 7(8):4867-76. PMC: 4152047. View

Bruun J, Kolberg M, Nesland J, Svindland A, Nesbakken A, Lothe R . Prognostic Significance of β-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. Front Oncol. 2014; 4:118. PMC: 4033250. DOI: 10.3389/fonc.2014.00118. View

Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou A . Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer. Tumour Biol. 2012; 33(4):1005-14. DOI: 10.1007/s13277-012-0333-3. View

Ting W, Chen L, Pao J, Yang Y, You B, Chang T . Common genetic variants in Wnt signaling pathway genes as potential prognostic biomarkers for colorectal cancer. PLoS One. 2013; 8(2):e56196. PMC: 3566082. DOI: 10.1371/journal.pone.0056196. View

Labadie J, Savas S, Harrison T, Banbury B, Huang Y, Buchanan D . Genome-wide association study identifies tumor anatomical site-specific risk variants for colorectal cancer survival. Sci Rep. 2022; 12(1):127. PMC: 8741984. DOI: 10.1038/s41598-021-03945-x. View

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Matsuoka T, Mitomi H, Fukui N, Kanazawa H, Saito T, Hayashi T . Cluster analysis of claudin-1 and -4, E-cadherin, and β-catenin expression in colorectal cancers. J Surg Oncol. 2011; 103(7):674-86. DOI: 10.1002/jso.21854. View

Wong S, Lo E, Chan A, Lee K, Hsiao W . Nuclear beta catenin as a potential prognostic and diagnostic marker in patients with colorectal cancer from Hong Kong. Mol Pathol. 2003; 56(6):347-52. PMC: 1187354. DOI: 10.1136/mp.56.6.347. View

10.

Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J, Jirstrom K . Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. Biol Sex Differ. 2011; 2:10. PMC: 3179695. DOI: 10.1186/2042-6410-2-10. View

11.

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

12.

Dong Z, Zheng L, Liu W, Wang C . Association of mRNA expression of TP53 and the TP53 codon 72 Arg/Pro gene polymorphism with colorectal cancer risk in Asian population: a bioinformatics analysis and meta-analysis. Cancer Manag Res. 2018; 10:1341-1349. PMC: 5973318. DOI: 10.2147/CMAR.S164892. View

13.

Balzi M, Ringressi M, Faraoni P, Booth C, Taddei A, Boni L . B-cell lymphoma 2 and β-catenin expression in colorectal cancer and their prognostic role following surgery. Mol Med Rep. 2015; 12(1):553-60. DOI: 10.3892/mmr.2015.3385. View

14.

Netter J, Lehmann-Che J, Lambert J, Tallet A, Lourenco N, Soliman H . Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer. Bull Cancer. 2015; 102(2):117-25. DOI: 10.1016/j.bulcan.2014.12.010. View

15.

Filiz A, Senol Z, Sucullu I, Kurt Y, Demirbas S, Akin M . The survival effect of E-cadherin and catenins in colorectal carcinomas. Colorectal Dis. 2009; 12(12):1223-30. DOI: 10.1111/j.1463-1318.2009.01994.x. View

16.

Veloudis G, Pappas A, Gourgiotis S, Falidas E, Dimitriou N, Karavokiros I . Assessing the clinical utility of Wnt pathway markers in colorectal cancer. J BUON. 2017; 22(2):431-436. View

17.

Mohd Y, Balasubramanian B, Meyyazhagan A, Kuchi Bhotla H, Shanmugam S, Ramesh Kumar M . Extricating the Association Between the Prognostic Factors of Colorectal Cancer. J Gastrointest Cancer. 2020; 52(3):1022-1028. DOI: 10.1007/s12029-020-00535-4. View

18.

Chen J, Tang H, Wu Z, Zhou C, Jiang T, Xue Y . Overexpression of RBBP6, alone or combined with mutant TP53, is predictive of poor prognosis in colon cancer. PLoS One. 2013; 8(6):e66524. PMC: 3684577. DOI: 10.1371/journal.pone.0066524. View

19.

Jurach M, Meurer L, Moreira L . Expression of the p53 protein and clinical and pathologic correlation in adenocarcinoma of the rectum. Arq Gastroenterol. 2006; 43(1):14-9. DOI: 10.1590/s0004-28032006000100006. View

20.

Theodoropoulos G, Karafoka E, Papailiou J, Stamopoulos P, Zambirinis C, Bramis K . P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. Anticancer Res. 2009; 29(2):785-91. View